Benefits from the generic drugs were much smaller, although their low costs made them more cost-effective
Regular Follow-Up Visits Lab tests are part of your visits, but not the only part
Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes
Our providers will review your history and discuss your goals
Conclusions and Future Perspectives Overall, GLP-1RAs are considered novel blood glucose lowering drugs used in the treatment of T2MD (229), owing to their advantages of lowering blood pressure, lowering the levels of fasting blood glucose, lowering HbA1c, inducing weight loss, and being associated with a low incidence of hypoglycemia
